First Detection of Mycobacterium tuberculosis Clinical Isolates Harboring I491F Borderline Resistance rpoB Mutation in Myanmar
- PMID: 36342155
- PMCID: PMC9765286
- DOI: 10.1128/aac.00925-22
First Detection of Mycobacterium tuberculosis Clinical Isolates Harboring I491F Borderline Resistance rpoB Mutation in Myanmar
Keywords: I491F; Myanmar; Mycobacterium tuberculosis; rifampin resistance.
Conflict of interest statement
The authors declare no conflict of interest.
References
-
- World Health Organization. 2021. Global tuberculosis report 2021. World Health Organization, Geneva, Switzerland. https://www.who.int/teams/global-tuberculosis-programme/tb-reports.
-
- World Health Organization. 2019. Global tuberculosis report 2019. World Health Organization, Geneva, Switzerland. https://www.who.int/teams/global-tuberculosis-programme/tb-reports.
-
- National Tuberculosis Program and WHO Country Office (Myanmar). 2017. Guidelines for management of drug resistant tuberculosis (DR-TB) in Myanmar February 2017. National Tuberculosis Program and WHO Country Office, Myanmar. https://www.aidsdatahub.org/sites/default/files/resource/myanmar-guideli....
-
- Rahman A, Sahrin M, Afrin S, Earley K, Ahmed S, Rahman SM, Banu S. 2016. Comparison of Xpert MTB/RIF assay and GenoType MTBDRplus DNA probes for detection of mutations associated with rifampicin resistance in Mycobacterium tuberculosis. PLoS One 11:e0152694. doi:10.1371/journal.pone.0152694. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
